A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder

Journal of Urology

Volumn 171, Issue 1, 2004, Pages 153-157

  Koga, Hirofumi ^a   Kuroiwa, Kentaro ^a   Yamaguchi, Akito ^a,b   Osada, Yukio ^a,c   Tsuneyoshi, Masazumi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HARASANSHIN HOSPITAL   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Administration, intravesical; Drug therapy, epirubicin; Randomized controlled trial, bladder neoplasms

Indexed keywords

EPIRUBICIN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSURIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY FREQUENCY;

EID: 0348109412     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000100386.07370.0a     Document Type: Article

References (20)

1. Soloway, M. S.: Intravesical therapy for bladder cancer. Urol Clin N Amer, 15: 661, 1988
2. Nilsson, S., Ragnhammar, P., Glimelius, B., Nygen, P. and SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol, 40: 371, 2001
3. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325: 1205, 1991
4. Badalament, R. A. and Farah, R. N.: Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol, 13: 335, 1997
5. Ali-El-Dein, B., El-Baz, M., Aly, A. N. M., Shamaa, S. and Ashamallah, A.: Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol, 158: 68, 1997
6. Ali-el-Dein, B., Nabeeh, A., el-Baz, M., Shamaa, S. and Ashamallah, A.: Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol, 79: 731, 1997
7. Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R. et al: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 149: 749, 1993
8. Melekos, M. D., Dauaher, H., Fokaefs, E. and Barbalias, G.: Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol, 147: 371, 1992
9. Solsona, E., Iborra, I., Ricós, J. V., Monrós, J. L., Casanova, J. and Dumont, R.: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short- and long-term followup. J Urol, 161: 1120, 1999
10. Okamura, K., Kinukawa, T., Tsumura, Y., Otani, T., Itoh, H., Kobayashi, H. et al: A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol, 33: 285, 1998
11. Nomata, K., Noguchi, M., Kanetake, H., Tsuda, N., Hayashi, M., Yamashita, S. et al: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol, 50: 266, 2002
12. Flamm, J.: Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol, 17: 119, 1990
13. Tolley, D. A., Parmar, M. K. B., Grigor, K. M., Lallemand, G. and the Medical Research Council Superficial Bladder Cancer Working Party: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol, 155: 1233, 1996
14. Mostofi, F. K., Sobin, H. L. and Torloni, H.: Histological typing of urinary bladder tumours. International Classification of Tumours, No. 10. Geneva, Switzerland: World Health Organization, 1973
15. Holford, T. R.: Life tables with concomitant information. Biometrics, 32: 587, 1976
16. Cersosimo, R. J. and Hong, W. K.: Epirubicin; a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol, 4: 425, 1986
17. Ueda, T., Naito, S., Iguchi, A., Sagiyama, K., Osada, Y., Ariyoshi, A. et al: Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol, suppl., 30: S31, 1992
18. Naito, S., Kotoh, S., Omoto, T., Osada, Y., Sagiyama, K., Iguchi, A. et al: Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol, 42: 367, 1998
19. Akaza, H.: New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence. Gan To Kagaku Ryoho, suppl., 24: 253, 1997
20. Hinotsu, S., Akaza, H., Ohashi, Y. and Kotake, K.: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by Japanese Urological Cancer Research Group using smoothed hazard function. Cancer, 86: 1818, 1999